Continuing coverage: A collaborative effort involving UTMB and three other entities aims to develop vaccines and treatments for the Ebola and Marburg viruses with the help of a federal grant worth up to $26 million. The National Institutes of Health awarded UTMB, Profectus Biosciences, Tekmira Pharmaceuticals and the Vanderbilt University Medical Center the sizable grant, which will be doled out over five years. Thomas Geisbert, a professor in UTMB’s Department of Microbiology and Immunology, will lead the research at UTMB.